These observations directly suggest that both sebaceous carcinoma and sweat gland carcinoma could be potentially treated with TROP2-targeted antibody–drug conjugates such as sacituzumab govitecan. The gene discussed is TACSTD2; the disease is sweat gland carcinoma.